CFRA analyst Wan Nurhayati lowered the price target on GlaxoSmithKline (NYSE: GSK) to $40.00 (from $42.00) while maintaining a Hold ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE